Rostoker G, Wirquin V, Terzidis H, Petit-Phar M, Chaumette M T, Delchier J C, Belghiti D, Lang P, Dubert J M, Meignan M
Department of Nephrology, INSERM-U 139, Henri-Mondor Hospital, Créteil, France.
Nephron. 1993;63(3):286-90. doi: 10.1159/000187211.
To study the specificity of gut hyperpermeability in primary glomerulonephritis, we investigated intestinal permeability by means of 51Cr-EDTA testing in 20 healthy individuals and in 30 patients with Immunoglobulin A nephropathy (IgA GN), 25 with idiopathic nephrotic syndrome (INS) and 20 with immune complex glomerulonephritis (IC-GN; membranous+membranoproliferative glomerulonephritis). Gut permeability was statistically increased in each patient group versus the controls [controls: 2% (0.4-3.9); IgA GN: 3.25% (0.7-17.70); INS: 3.71% (0.82-10); IC-GN: 3.40% (0.30-16); results are median (range); p < 0.005, nonparametric Mann-Whitney test]. An increase in intestinal permeability exceeding the upper limit of control values (95th percentile) was observed in 36% of IgA GN, 60% of INS and 50% of IC-GN patients. We conclude that intestinal permeability is frequently increased in primary glomerulonephritis and may also be increased in types of glomerulonephritis other than IgA GN.
为研究原发性肾小球肾炎中肠道高通透性的特异性,我们通过51Cr-乙二胺四乙酸(51Cr-EDTA)检测法,对20名健康个体以及30例免疫球蛋白A肾病(IgA GN)患者、25例特发性肾病综合征(INS)患者和20例免疫复合物性肾小球肾炎(IC-GN;膜性+膜增生性肾小球肾炎)患者的肠道通透性进行了调查。与对照组相比,各患者组的肠道通透性均有统计学意义上的升高[对照组:2%(0.4-3.9);IgA GN:3.25%(0.7-17.70);INS:3.71%(0.82-10);IC-GN:3.40%(0.30-16);结果为中位数(范围);p<0.005,非参数曼-惠特尼检验]。在36%的IgA GN患者、60%的INS患者和50%的IC-GN患者中,观察到肠道通透性增加超过了对照值的上限(第95百分位数)。我们得出结论,原发性肾小球肾炎患者的肠道通透性经常增加,并且在除IgA GN以外的其他类型肾小球肾炎中也可能增加。